文献速递心境障碍

基于丘脑-感觉运动功能连接的通用分层预测抑郁症抗抑郁药反应

Generalizable stratification based on thalamo-somatomotor functional connectivity predicts responses to antidepressants in patients with depression.
PubMed 文献 · Mol Psychiatry · 2025-09-20

该研究利用两个多站点数据集构建并验证基于静息态功能连接(rs-FC)的抑郁症分层生物标志物。最稳定的标志物基于丘脑与中央后回之间的若干rs-FC,据此分层的MDD亚型对选择性5-羟色胺再摄取抑制剂(SSRI)治疗反应显著不同。通过缩减特征维度避免过拟合,成功构建了可推广的分层标志物。

要点

  • 基于丘脑与中央后回间rs-FC的分层标志物可区分MDD亚型。
  • 不同亚型对SSRI治疗的反应存在显著差异。
  • 缩减特征维度有助于避免过拟合并提高标志物可推广性。

核心结论

  • 基于丘脑与中央后回之间若干静息态功能连接构建的分层生物标志物具有可推广性,所分层的MDD亚型对SSRI治疗反应显著不同。

研究设计与样本

  • 研究利用两个多站点数据集,采用无监督学习基于MDD诊断生物标志物中排名靠前的rs-FC子集构建分层生物标志物,并识别最稳定的标志物。

主要发现

  • 最稳定的分层标志物基于丘脑与中央后回之间的若干rs-FC。
  • 由该标志物分层的MDD亚型对选择性5-羟色胺再摄取抑制剂治疗的反应显著不同。

临床怎么用

  • 该分层标志物可能有助于推动MDD患者的个性化精准医疗。

局限性

  • 原文指出功能磁共振成像数据存在固有测量与采样偏倚,且可能对发现队列过拟合,缺乏可推广性是既往分层生物标志物研究的问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Major depressive disorder (MDD) is diagnosed based on signs and symptoms without relying on physical, biological, or cognitive tests. Patients with MDD exhibit a wide range of complex symptoms, and diverse underlying neurobiological backgrounds have been assumed. If biomarkers can stratify patients with MDD into biologically homogeneous subtypes, personalized precision medicine would be within reach. Some studies have used resting-state functional connectivity (rs-FC) to stratify and predict treatment responses for MDD subtypes. However, few studies have demonstrated the reproducibility (i.e., generalizability) of stratification biomarkers in independent validation cohorts. Lack of generalizability may be due to inherent measurement and sampling biases in functional magnetic resonance imaging (fMRI) data and overfitting to discovery cohorts. To address this problem, we previously constructed a multisite, multidisorder fMRI database from thousands of participants, proposed a hierarchical supervised-unsupervised learning strategy, and developed generalizable diagnostic biomarkers of MDD via supervised learning. Using unsupervised learning, we constructed here stratification biomarkers for patients with MDD based on subsets of the top-ranked rs-FCs in MDD diagnostic biomarkers. We utilized two multisite datasets, constructed stratification biomarkers, and identified the most stable biomarker. The identified biomarker was based on several rs-FCs between the thalamus and postcentral gyrus. MDD subtypes stratified by this biomarker showed significantly different responsiveness to treatment with a selective serotonin reuptake inhibitor. By narrowing down the feature dimensions, we avoided overfitting to the training data and successfully constructed a generalizable stratification biomarker. This biomarker might have the potential to facilitate personalized precision medicine for patients with MDD.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kashiwagi Y, Tokuda T, Takahara Y, et al. Generalizable stratification based on thalamo-somatomotor functional connectivity predicts responses to antidepressants in patients with depression. Mol Psychiatry. 2025. PMID: 40975750. doi:10.1038/s41380-025-03224-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。